#United States #Avertix Medical #Guardian System #Joseph Berardo #EATONTOWN

Avertix Medical Expands Leadership with Key Board Appointments

Avertix Medical, a leader in innovative medical devices, has made strategic enhancements to its Board of Directors aimed at reinforcing its mission of advancing cardiovascular care. This restructuring comes in light of the increasing importance of real-time heart attack detection and showcases Avertix’s commitment to leading the way in cardiac technology.

New Chairman Established

Joseph Berardo, Jr., who has been a member of the board, has been appointed as the new Chairman, succeeding Ross Haghighat. Berardo brings with him an extensive track record as Chairman and CEO of Carisk Partners, where he has successfully built high-performing teams and delivered substantial value in the healthcare services arena. His leadership is expected to further strengthen Avertix’s direction in the burgeoning field of cardiovascular health technology.

Welcoming New Board Members

In addition to the new chairperson, Avertix has welcomed three distinguished new members to its board:

• - Dr. Richard Schatz: An internationally recognized name in interventional cardiology, Dr. Schatz co-invented the life-saving Palmaz-Schatz coronary stent. His work has been transformative in treating coronary artery disease, impacting millions of patients globally. He also holds an Adjunct Professorship at Duke University after a key role at the Scripps Heart, Lung, and Vascular Center.
• - Christopher Pucillo: As the founder of Solus Alternative Asset Management, Pucillo’s expertise spans credit and leveraged loan trading. Having occupied senior positions at renowned firms like Morgan Stanley, he brings invaluable financial acumen to Avertix, enabling the company to navigate the complexities of the healthcare market strategically.
• - Sean E. Cullinan: The former President of Columbus Hill Capital Management, Cullinan possesses vast experience in overseeing global investments across various securities. His past roles include leadership positions at PointState Capital and Soros Fund Management, underlining his extensive background in capital management.

CEO’s Vision

Tim Moran, President and CEO of Avertix Medical, expressed enthusiasm about the new appointments, emphasizing their potential to transform the company’s trajectory in cardiac care. He stated, "I am thrilled to announce the addition of Joe Berardo, Jr., as our new Chairman and three distinguished Board members. Their collective expertise and vision come at a pivotal time in our evolution as we continue to grow and transform the landscape of cardiac care for patients who suffer from Acute Coronary Syndrome events. The enhancement of our Board of Directors underscores our commitment to advancing innovation, driving strategic growth, and delivering life-saving solutions to patients and healthcare providers. Together, we are poised to navigate the next phase of our journey with confidence and purpose."

The Guardian System: A Revolutionary Approach to Cardiac Care

Avertix Medical’s flagship product, the Guardian System, is a pioneering Class III implantable device that continuously monitors heart activity to detect silent and atypical heart attacks in real-time. This device is implanted subcutaneously by healthcare professionals through a straightforward outpatient procedure. Utilizing machine learning algorithms, the Guardian System establishes a patient’s baseline and can promptly identify concerning shifts in the ST segment of the heart’s electrical activity, offering critical alerts ahead of symptomatic manifestations.

As a leader in this innovative space, Avertix Medical not only seeks to enhance the efficiency of heart attack diagnoses but also aims to reshape patient outcomes dramatically. With these leadership changes, the company is well-positioned to push boundaries in the healthcare industry continually.

Avertix Medical stands out as a beacon of innovation, focused on delivering advanced solutions that could save lives and improve the quality of life for countless individuals, cementing its role as a pivotal player in cardiology.

For further insights and updates, check out Avertix Medical's website.